Bufotaline

Research use only, not for human use.

Bufotaline is a kind of poisonous secretions of toads.

Bufotaline is a kind of poisonous secretions of toads.

Bufotalin (0.1-2.5 μM; 12-96 hours) treatment dose- and time-dependently inhibits MG-63 osteoblastoma cell survival. Bufotalin (0.5-2.5 μM; 48 hours) treatment dose-dependently increases the percentage of Annexin V positive cells (apoptotic cells) and caspase-12 activity in MG-63 cells. Bufotalin-induced osteoblastoma cell apoptosis is associated with caspase-12 activation. Bufotalin (0.5-2.5 μM; 12 hours) treatment dose-dependently induces C/EBP homologous protein (CHOP) expression as well as PERK and IRE1 phosphorylation in MG-63 cells. Bufotalin induces endoplasmic reticulum (ER) stress activation in cells. Bufotalin treatment induces cell cycle arrest at G2/M phase through down-regulation of Aurora A, CDC25, CDK1, cyclin A and cyclin B1, as well as up-regulation of p53 and p21 in HepG2 cells. Bufotalin treatment also induces apoptosis which was accompanied by decrease in mitochondrial membrane potential, increases in intracellular calcium level and reactive oxygen species production, activations of caspase-9 and -3, cleavage of poly ADP-ribose polymerase (PARP) as well as changes in the expressions of bcl-2 and bax.Cell Viability Assay Cell Line:MG-63 osteoblastoma cells Concentration:0.1 μM, 0.5 μM, 1 μM, 2.5 μM Incubation Time:12 hours, 24 hours, 48 hours, 72 hours, 96 hours Result:Inhibited MG-63 osteoblastoma cell survival. Apoptosis Analysis Cell Line:MG-63 cells Concentration:0.5 μM, 1 μM, 2.5 μM Incubation Time:48 hours Result:Dose-dependently increased the percentage of Annexin V positive cells (apoptotic cells) and caspase-12 activity in MG-63 cells.Western Blot Analysis Cell Line:MG-63 cells Concentration:0.5 μM, 1 μM, 2.5 μM Incubation Time:12 hours Result:Dose-dependently induced CHOP expression as well as PERK and IRE1 phosphorylation in MG-63 cells.

Bufotalin (0.5-1 mg/kg; intraperitoneal injection; twice daily; for 7 days) treatment shows a significantly reduced tumor growth in mice. Animal Model:SCID male mice (4-6 weeks old) injected with U2OS cells Dosage:0.5 mg/kg, 1 mg/kg Administration:Intraperitoneal injection; twice daily; for 7 days Result:Inhibited U2OS osteoblastoma cell growth in mice.

——

Others

Other Targets

Others

Cancer

——

471-95-4

444.56

C26H36O6

>98% (HPLC)

DMSO : ≥ 4.6 mg/mL; 10.35 mM

CC(=O)OC1CC2(C3CCC4CC(CCC4(C3CCC2(C1C5=COC(=O)C=C5)C)C)O)O

——

(-20℃)

With Ice Pack

≥ 2 years